Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2)

Rationale. The rising incidence of type 2 diabetes mellitus (T2DM) allows researchers to conduct observational multicentre studies and obtain objective information about the epidemiology of diabetes and its complications and evaluate the efficacy of different therapies and diagnostic strategies designed to identify systemic vascular complications.

Aims. To analyse epidemiological and socio-demographic parameters, the quality of glycaemic control, diagnostic monitoring and therapeutic measures typical among patients with T2DM living in Russian towns of different populations.

Materials and methods. FORSIGHT-DM2 is an all-Russian multicentre observational epidemiological study that involves 2014 patients with T2DM from 45 different towns in the Russian Federation (RF). All patients have had T2DM for at least 1 year. They received glucose-lowering therapy and primary medical care from RF public outpatient health institutions between 01.01.2014 and 31.12.2014. For comparative analysis of the typical treatment for patients with T2DM, we stratified patients into groups based on the number of residents.

Results. The data reveal a lack of glycaemic control (average НbА1с 7.9% ± 1.9%), with НbА1с > 8% in 36% of patients. The frequency of T2DM complications was high and the prevalence of retinopathy was 63.2%, nephropathy was 34.4% (7.8% had chronic kidney disease G3a-G5), peripheral polyneuropathy was 63.3%, ‘diabetic foot’ syndrome was 13.7% and osteoarthropathy was 5%. The number of T2DM-related complications is correlated with the HbA1c level and disease duration. Moreover, simultaneous influence of these factors led to a significant increase in the number of chronic complications associated with T2DM (r = 0.338 for T2DM duration, r = 0.262 for HbA1c; р < 0.001). Despite the high frequency of patient consultations with endocrinologists (83%) and a large percentage of hospitalisations in the current year (46%), the screening of chronic complications of T2DM in 2014 is insufficient.

Conclusion. The results indicate insufficient glycaemic control among patients with T2DM and a higher prevalence of chronic complications compared with the national register of diabetic patients.

1. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития // Сахарный диабет. – 2015. – Т. 18. – №3 – C. 5-22. [Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation. Diabetes mellitus. 2015;18(3):5-22. (In Russ)] doi: 10.14341/DM201535-22

2. Dedov I, Shestakova M, Benedetti MM, et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-95. doi: 10.1016/j.diabres.2016.02.010

3. Старостина Е.Г. Биомедицинские и психосоциальные аспекты сахарного диабета и ожирения: взаимодействие врача и пациента и пути его оптимизации. Автореферат дисс. … док.мед. наук. М; 2003. [Starostina EG. Biomeditsinskie i psikhosotsial’nye aspekty sakharnogo diabeta i ozhireniya: vzaimodeystvie vracha i patsienta i puti ego optimizatsii. [[dissertation] Moscow; 2003. (In Russ)]

4. Сахарный диабет: диагностика, лечение, профилактика. / Под ред. И.И.Дедова, М.В.Шестаковой. – М.: ООО «Издательство «Медицинское информационное агенство»; 2011. [Sakharnyy diabet: diagnostika, lechenie, profilaktika. Ed by II Dedov, MV Shestakova. Moscow: OO2Izdatel’stvo «Meditsinskoe informatsionnoe agenstvo»; 2011. (In Russ).]

5. Сунцов Ю.И., Дедов И.И. Государственный регистр больных сахарным диабетом – основная информационнная система для расчета экономических затрат государства на сахарный диабет и их прогнозирование // Сахарный диабет. – 2005. – Т. 8. – №2 – C. 2-5. [Suntsov YI, Dedov II. Gosudarstvennyy registr bol’nykh sakharnym diabetom – osnovnaya informatsionnnaya sistema dlya rascheta ekonomicheskikh zatrat gosudarstva na sakharnyy diabet i ikh prognozirovanie. Diabetes mellitus. 2005;8(2):2-5. (in Russ)]. doi: 10.14341/2072-0351-5773

6. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007-2012 годы» // Сахарный диабет. – 2013. – Т. 16. – №2S – C. 1-48. [Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme ‘Prevention and Management of Socially Significant Diseases (2007-2012)’: results of the ‘Diabetes mellitus’ sub-programme. Diabetes mellitus. 2013;16(2S):1-48.(In Russ)] doi: 10.14341/2072-0351-3879

7. Дедов И.И., Омельяновский В.В., Шестакова М.В., и др. Cахарный диабет как экономическая проблема в Российской Федерации // Сахарный диабет. – 2016. – Т. 19. – №1 – C. 30-43. [Dedov II, Omelyanovskiy VV, Shestakova MV, Avksentieva MV, Ignatieva VI. Diabetes mellitus as an economic problem in Russian Federation. Diabetes mellitus. 2016;19(1):30-43. (In Russ).]. doi: 10. 14341/DM 7784

8. Шестакова М.В. Реальная клиническая практика лечения сахарного диабета 2 типа в Российской Федерации по данным открытой проспективной наблюдательной программы ДИА-КОНТРОЛЬ? // Сахарный диабет. – 2011. – Т. 14. – №4 – C. 75-80. [Shestakova MV. Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospective observational study DIA-CONTROL? Diabetes mellitus. 2011;14(4):75-80. doi: 10.14341/2072-0351-5822 (In Russ)]

9. Шестакова М.В. Программа A1chieve в России: многоцентровое проспективное наблюдательное исследование эффективности и безопасности начала и интенсификации инсулинотерапии с помощью аналогов инсулина у пациентов с сахарным диабетом 2 типа, ранее не получавших инсулин, в повседневной клинической практике // Сахарный диабет. – 2012. – Т. 15. – №1 – C. 63-70. [Shestakova MV. A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before. Diabetes mellitus. 2012;15(1):63-70. (In Russ)] doi: 10.14341/2072-0351-5981

10. Massi-Benedetti M, Board C-A. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia. 2002;45(7):S1-4. doi: 10.1007/s00125-002-0860-3

11. Alvarez Guisasola F, Mavros P, Nocea G, et al. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab. 2008;10 Suppl 1:8-15. doi: 10.1111/j.1463-1326.2008.00881.x

12. Valensi P, Benroubi M, Borzi V, et al. The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62(11):1809-1819. doi: 10.1111/j.1742-1241.2008.01917.x

13. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. – 2015. – Т. 18. – №1S – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (In Russ)] doi: 10.14341/DM20151S1-112

14. Приказ Минздрава России от 12 ноября 2012 г. N 899н «Порядок оказания медицинской помощи взрослому населению по профилю «эндокринология» [Prikaz Minzdrava Rossii ot 12 noyabrya 2012 g. N 899n «Poryadok okazaniya meditsinskoy pomoshchi vzroslomu naseleniyu po profilyu «endokrinologiya» (In Russ)]: Available from: https://www.rosminzdrav.ru/documents/5479-prikaz-minzdrava-rossii-ot-12-noyabrya-2012-g-n-899n